Region: European Union

What leaked US trade talks tell us about future of UK pharma IP

Secret government documents detailing pharma patent discussions between UK and US officials have stirred up a controversy in the run up to the British general election later this month

04 December 2019

Shorter EPO opposition process requires new approaches from life sciences patentees

Strategies employed not only by rights owners but also by those opposing their grants will need to be recalibrated to reflect the new realities

19 November 2019

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms

14 November 2019

EPO agreement to boost Chinese companies' Europe push

Foreign companies with R&D in China may also benefit from deal opening up PCT search options

13 November 2019

US government patent suit against Gilead could be a sign of things to come

After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016

12 November 2019

Catch up on the most important life sciences IP developments from the past month

Read our most recent monthly round-up for key pharma and biotech IP stories from October 2019

08 November 2019

Monsanto prevails in key $7.7 billion Brazilian licensing lawsuit

In a big win for patent owners, the first-of-its-kind ruling upholds biotech innovators’ rights to collect royalties on saved GM seeds

05 November 2019

UK general election could result in a paradigm shift on pharma IP

The Labour Party – the main opposition to Boris Johnson’s Conservatives – recently set out a radical plan to change the patent regime for life sciences innovators

02 November 2019

Four key IP implications from the rise of orphan drugs

The growing importance of rare disease treatments has strategic, commercial and potential political ramifications for life sciences IP

29 October 2019

Trade secrets pitfalls in the life sciences – and how to avoid them

Proprietary information and data are vital sources of commercial advantage for biopharma companies, so keeping them safe is a vitally important task

22 October 2019

Unlock unlimited access to all IAM content